List your company

Multi-class classification on new-thyroid (F1, G-mean)

99.5F1-scoreIMOVNO+
28.197646.708865.2283.7312Feb 22, 2026

Evaluation results

MethodLinks
IMOVNO+validation=5-fold cross-validation2026.0299.599.5299.599.49—
IMOVNO+Validation=5-fold cross-validation2026.0299.599.5299.599.49—
IMOVNO+Binarization=true, Cross-validation=5-fold2026.0299.599.5299.599.49—
IMOVNO+Evaluation Protocol=5-fold cross-validation2026.0299.5——99.4999.5
IMOVNO+Strategy=Binarization, Validation=5-fold cross-validation2026.0299.599.5299.599.49—
MDGP-Forestvalidation=5-fold cross-validation2026.0296.54——97.12—
SVM-E-EVRSEvaluation Protocol=5-fold cross-validation2026.0295.6——96.3—
OVO-ISMOTEBinarization=true, Cross-validation=5-fold2026.0294.9395.1995.3295.03—
OVO-ISMOTEStrategy=Binarization, Validation=5-fold cross-validation2026.0294.9395.1995.3295.03—
DT-E-EVRSEvaluation Protocol=5-fold cross-validation2026.0294.9——95.2—
CPSQSVMEvaluation Protocol=5-fold cross-validation2026.0293.81———96.09
FEHCvalidation=5-fold cross-validation2026.0292.390.5195.24——
OVO-HSCFBinarization=true, Cross-validation=5-fold2026.0292.1894.0891.5990.81—
OVO-HSCFStrategy=Binarization, Validation=5-fold cross-validation2026.0292.1894.0891.5990.81—
GDHSvalidation=5-fold cross-validation2026.0291.3989.9893.6293.33—
SAMME.C2Validation=5-fold cross-validation2026.0284.9282.9488.5380.71—
OVO-GDDSADBinarization=true, Cross-validation=5-fold2026.0274.7173.9778.2977.48—
OVO-GDDSADStrategy=Binarization, Validation=5-fold cross-validation2026.0274.7173.9778.2977.48—
ECDNNValidation=5-fold cross-validation2026.0235.5440.4935.472.61—
SMOTE-CDNNValidation=5-fold cross-validation2026.0230.9439.9955.8450.32—